Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR1D | P28221 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12959262 | 0.82 | TAAR1 (0.48) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL10822849 | 0.82 | TAAR1 (0.43) | TAAR1CYP1A2CYP2A6MAPTRXFP1 | |
| SCHEMBL598593 | 0.81 | TAAR1 (0.44) | TAAR1CYP1A2CYP2A6MAPTRXFP1 | |
| SCHEMBL1869457 | 0.80 | TAAR1 (1.00) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL855681 | 0.80 | TAAR1 (0.69) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL30251350 | 0.80 | TAAR1 (0.69) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL13846533 | 0.79 | HTR2A (0.46) | TAAR1HTR2ABACE1 | |
| SCHEMBL24809090 | 0.79 | TAAR1 (0.56) | TAAR1HTR2AHTR1DBACE1HTR1A | |
| Methane SCHEMBL27570896 | 0.79 | TAAR1 (0.43) | TAAR1CYP1A2CYP2A6POLBMAPT | |
| Hydrochloric Acid SCHEMBL18448337 | 0.78 | TAAR1 (0.67) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434747-B2 | Methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140228353-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228353-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | TAAR1 131/4885HTR2A 5/4885HTR1D 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.